Keyword : breast cancer
A Multidisciplinary Approach to Breast Cancer Treatment in Historical Perspective
Cost minimization analysis of neoadjuvant treatment of luminal B HER2/neu-negative breast cancer: chemotherapy versus hormone therapyAuthors: Artemenko M.V. Bondarenko I.M. Zavizion V.F. Avierin D.I. Дата: 2025-01-08
Features of immune microenvironment in Her2 low breast cancerAuthors: Lyalkin S.A. Krotevich M.S. Smolanka I.I. Shudrak P.A.... Т. 14, №3 (55)
Neoadjuvant endocrine therapy of breast cancer: history and modern views of the problem
Authors: Zavizion V.F. Artemenko M.V. Т. 14, №3 (55)
Authors: Zavizion V.F. Artemenko M.V. Т. 14, №3 (55)
Assessment of the toxicity profile and safety of integrating metformin into neoadjuvant chemotherapy for breast cancerAuthors: Avierin D. Zavizion V. Т. 14, №2 (54)
Analysis of the relationship between Ki-67 expression dynamic and RECIST 1.1 dynamic during neoadjuvant breast cancer chemotherapy. Prediction of morphological responseAuthors: Avierin D. Zavizion V. Т. 14, №1 (53)
Plasma miRNA levels in breast cancer patients and their correlation with clinical characteristics as a measure of individualized treatment
Author:Harashchenko О. Т. 14, №1 (53)
Author:Harashchenko О. Т. 14, №1 (53)
New stage in personalized breast cancer therapy: a chance for recovery
Treatment of patients with recurrent and metastatic forms of breast cancerAuthors: Ivankova V.S. Baranovska L.M. Stoliarova O.Yu. Ivankova O.M.... Т. 13, № 3 (51)
New stage in personalized breast cancer therapy: a chance for recovery
The course features of HER2/neu-low breast cancerAuthors: Bondar M.V. Syvak L.A. Tarasenko T.Ye. Martynyuk O.M.... Т. 13, № 2 (50)
Clinical characteristics, treatment characteristics, and endpoints assessed in real-world clinical practice of talazoparib in patients with HER2-negative BRCA-associated breast cancerAuthor:Huyvanyuk O.A. Т. 13, № 2 (50)
Comparative analysis of the use of radiopharmaceuticals in the treatment of bone metastasesAuthors: Solodyannуkova O.I. Danylenko V.V. Т. 12, № 3-4 (47-48)
Effect of chemokin polymorphisms on the efficacy of chemotherapy in patients with Her2/neu-negative breast cancerAuthors: Syvak L. Verovkina N.O. Lyalkin S. Tarasenko T.... Т. 11, № 3-4 (43-44)
Clinical cases of treatment of bone lesions in breast and prostate cancer (radionuclide therapy)Authors: Danilenko V.V. Sukach G.G. Solodyannikova O.I. Sagan D.L. T. 10, № 1-2 (37-38)
